Patents by Inventor Wiltrud LEDERLE

Wiltrud LEDERLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
    Patent number: 11951166
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: April 9, 2024
    Assignee: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
    Patent number: 11517622
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: December 6, 2022
    Assignee: BAYER HEALTHCARE LLC
    Inventors: Sabine Hoff, Lars Rose, Dieter Zopf, Fabian Kiessling, Wiltrud Lederle, Dennis Doleschel
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20220133888
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: January 14, 2022
    Publication date: May 5, 2022
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars RÖSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200188372
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: December 31, 2019
    Publication date: June 18, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200179354
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: May 25, 2018
    Publication date: June 11, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL
  • COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER
    Publication number: 20200155674
    Abstract: The present invention relates to pharmaceutical compositions and combinations comprising regorafenib or its hydrate, solvate, metabolite or pharmaceutically acceptable salt or a polymorph thereof and a PD-1/PD-L1(2) inhibitor for treating, preventing or managing diseases and conditions including hyperproliferative disorders such as cancer in humans and other mammals.
    Type: Application
    Filed: December 31, 2019
    Publication date: May 21, 2020
    Applicant: BAYER AKTIENGESELLSCHAFT
    Inventors: Sabine HOFF, Lars ROSE, Dieter ZOPF, Fabian KIESSLING, Wiltrud LEDERLE, Dennis DOLESCHEL